Maxim Ceplene Promotions At ASCO Draw Second FDA Letter In Six Months
Executive Summary
Maxim's Ceplene promotions at the American Society of Clinical Oncology conference in May are the subject of the second letter to the company from FDA's ad division in less than six months.